Maximakinin, a 19-residue peptide from the amphibian Bombina maxima, incorporates the full sequence of bradykinin (BK) at its C-terminus with a hydrophilic 10-residue N-terminal Maximakinin is the first known natural kinin sequence that elicits a prolonged cellular signalling, thus suggesting a possible basis for a venomous action and a naturally selected one for the design of B 2 R-transported biotechnological cargoes.
Introduction
Maximakinin, a natural sequence isolated from the skin of the amphibian Bombina maxima, is composed of the full bradykinin (BK) sequence at its C-terminal region with a 10-residue Nterminal extension (a 19-mer; primary structure in Table 1 ); this peptide is reportedly pharmacologically active in mammalian tissues [1] . In the genome of B. maxima, there are 5 identical copies of the maximakinin coding sequence found in 2 predicted and cleavable proteins secreted from cells present in skin secretions [2] , supporting that the peptide serves a vital function in this animal. Thus, if maximakinin is an ingredient of toxic and/or dissuasive animal venom, it may possess intrinsic signaling properties different from those of BK, e.g., exerting prolonged signaling at the high affinity B 2 receptor (B 2 R). Polistes kinin is one of the BK-related peptides found in the venom of a subgroup of Hymenoptera insects; it resembles maximakinin by including the full BK sequence at its C-terminus and a hydrophilic and cationic N-terminal extension of 9 residues [3] (Table 1) . Angiotensin converting enzyme (ACE), an ectopeptidase highly active to inactivate BK, exhibits a rapidly decreasing affinity for higher homologues of BK prolonged at the N-terminus, although this enzyme attacks the opposite end of the BK sequence by hydrolysing a C-terminal dipeptide; thus, Polistes kinin is completely protected from inactivation by ACE [4] .
Recent discoveries based on the use of synthetic B 2 R agonists show the role of endosomal inactivation in the duration of signalling and rate of recycling of endocytosed B 2 R back to the cell surface. The agonist peptide B-9972 (D-Arg-[Hyp 3 , Igl 5 , Oic 7 , Igl 8 ]-BK; Table 1 ) and a nonpeptide partial agonist drug structurally derived from an antagonist, compound 47a, integrate resistance to many or all peptidases that may inactivate BK (amino-, carboxy-and endopeptidases) and they provoked the endocytosis of B 2 Rs for more than 12 h, with consequences such as prolonged ERK1/2 and c-Fos signalling, prolonged B 2 R association witharrestins in endosomes and measurable receptor downregulation (degradation) over 12 h [5, 6] .
BK only induced short term signalling and fully reversible receptor internalization (in 1-3 h).
Another laboratory has shown that endosom -arrestin-mediated signalling of the cognate NK 1 receptors [7] .
We determined whether maximakinin had affinity for and stimulated mammalian B 2 Rs and whether indications of its resistance to extra-or intracellular inactivation could be gathered in comparative experiments conducted with the mammalian agonist BK and some biologically active BK homologues presenting extended N-terminal sequences. Specifically, the duration of maximakinin-induced B 2 R endocytosis and signalling and the possible long-term receptor downregulation in cells treated with this kinin were points of particular interest. Complementary experiments on the mechanism of endosomal inactivation of BK were conducted. P. Corvol, Paris, France) was determined in transiently transfected HEK 293a cells as described [8] ; this binding is displaced by BK-related substrates [9] , which was verified for maximakinin.
Methods

Radioligand binding competition assays
BK was used in both binding assays as a reference.
Contractility assay
The institutional research ethics board approved the anonymous use of human umbilical cord segments obtained after elective cesarean sections. B 2 receptor agonists were assayed as described by the contraction of the human isolated umbilical vein [5, 6, 10] . Cumulative concentration-effect curves were constructed for maximakinin and its potency estimated by the half-maximal concentration (EC 50 ) and compared to that of the reference agonist BK.
Microscopy, cytofluorometry
Epifluorescence of GFP-tagged B 2 receptor (B 2 R-GFP) was observed in HEK 293 cells that stably express this construction in order to detect maximakinin-induced receptor endocytosis and cycling as a function of time [5, 6] . The effects of this kinin were compared to those of BK and of the inactivation-resistant BK analogue, B-9972. A variant consisted of a B 2 R-GFP recycling assay: the HEK 293 cells that stably express this fusion protein were stimulated with BK (100 nM) for a 3-h incubation period, after which the endocytosis of the receptor is fully reversible [5] .
Some cells were co-treated with various enzyme inhibitors to analyze the mechanism of the recycling.
Immunoblots
HEK 293 cells stably expressing B 2 R-GFP were treated with drugs for 30 min-12 h, lyzed and the immunoblots for B 2 R-GFP were performed as previously reported [5] , based on the monoclonal anti-GFP antibody JL8 (Clontech, Palo Alto, CA). The agonist action of maximakinin on the ERK1/2 MAP kinase phosphorylation assay was tested as described in HEK 293 cells stably expressing B 2 R-GFP or in HEK 293a cells expressing myc-B 2 Rs [5] . Induction of the expression of the transcription factor c-Fos is also a response to kinins in HEK 293a cells expressing myc-B 2 Rs, and has been detected as described [5] . 
Drugs
Results
Synthetic maximakinin exhibits a moderate loss of affinity relative to BK at the B 2 receptor (~12-fold in the competition assay for the radioligand binding to the rabbit receptor, ~8-fold in the human vein contractility; Fig. 1 cases, down to free GFP (Fig. 3) . BK was inactive at time 12 h when used at an equieffective concentration, as reported previously [6] . The two peptides that caused B 2 R-GFP downregulation induced a persistent endocytosis of this fusion protein (epifluorescence microscopy, Fig. 4 ), unlike BK that caused only an acute (30 min), but entirely reversible (3 h) translocation of the fluorescent receptor.
The resistance of maximakinin to endosomal inactivation possibly points out to the N-terminus of BK as structural determinant of vulnerability in this milieu. The B 2 R-GFP downregulation assay was applied to other BK homologues (Table 1) If the structure of the agonist determines the duration of the B 2 R cycling by affecting the degradation of the ligand, it should be possible to exploit the recycling of B 2 R-GFP to the plasma membrane in BK-stimulated cells (as in Fig. 4 ) to identify the pathways of BK degradation by co-treating the intact cells for 3 h with (Fig. 6 ) revealed that the cysteine protease inhibitor, E-64, blocked B 2 R-GFP recycling to the cell surface, unlike inhibitors of aspartyl or seryl proteases, pepstatin A or PMSF, respectively (Fig.   6 ). Additional inhibitors that showed some activity were the ACE blocker enalaprilat (partial recycling inhibition) and bafilomycin A1, a substance that inhibits the proton pump that acidifies intracellular organelles (Fig. 6 ).
Discussion
Effect of N-terminal structure of kinins on affinity for the B 2 R
Maximakinin has direct affinity for the mammalian B 2 R in a binding assay conducted on ice in the presence of peptidase and protease inhibitors (Fig. 1A) , suggesting that it is not a precursor transformed by the metabolism into BK or some other homologue of BK. The slight loss of affinity for the B 2 R is determined by the N-terminal extension in maximakinin, one log unit on the average. In the current model of BK docking to the B 2 R, a G protein coupled receptor, the Cterminal part of the ligand interacts with the trans-membrane domains, while the N-terminal end of BK rather binds to an extracellular loop [12] . Thus, N-terminally extended BK sequences may retain receptor affinity despite the limited accessibility of the B 2 R extracellular surface determined by heavy glycosylation [13] . In support of this, Met-Lys-BK exhibits an affinity only marginally inferior to that of BK for the recombinant human and mouse B 2 Rs [14] and Ile-Ser-BK, a sequence derived from rodent T-kininogen, also retains a good fraction (10-50%) of BK potency at mammalian B 2 Rs [15] . On the other hand, we recently reported an N-terminal extended analog, CF--ACA-BK, that was 400-1000-fold less potent than BK as an agonist of the B 2 R [10] (Table 1) . Present results suggest that considerable N-terminal extensions may be tolerated in B 2 R agonists if the amino acid sequence is optimized. In that regard, maximakinin exhibits an amphibian peptide extension that is hydrophilic and possesses spatially oriented by Gly -1 -Pro 0 , perhaps allowing more flexibility to meet binding requirements Polistes kinin, another higher homologue of BK from an animal venom, has a glycine residue at the -1 position (table 1) , which may be structurally equivalent [3] .
Extracellular inactivation of maximakinin
In the HEK 293/B 2 R-GFP cellular system, soluble ACE present in the fetal bovine serumcontaining culture medium mediates the main extracellular inactivation pathway for BK (t 1/2 < 10 min) [16] . HEK 293 cells do not express ACE unless transfected with a corresponding expression vector, based on both a [ 3 H]enalaprilat binding assay and an enzymatic assay [8, 17] . The partial inhibition of B 2 R-GFP recycling in 3 h in the presence of enalaprilat (Fig. 6 ) may be interpreted as the effect of the ~13-fold prolongation of the BK half-life in the culture medium when extracellular ACE is blocked [16] . However, ACE blockade does not importantly inhibit B 2 R-GFP recycling over a longer period (12 h) and leads only to a minor breakdown of the B 2 R-GFP protein relative to that induced by B-9972 [5] . Maximakinin is less active than BK to displace 
Intracellular inactivation of maximakinin and effects on signalling and B 2 R downregulation
Additional and ill-characterized endosomal peptidases degrade BK after the ligand-B 2 R complex internalization [18] . In endosomes, there is evidence that the ligand-B 2 R--arrestin complex is stable, based on the colocalization of CF---arrestin [10] or of B 2 R-GFP with arrestins [6] , and that signalling originates from such intracellular complexes [19] . Maximakinin stands out as an agonist resistant to intracellular inactivation based on the kinetics of both the signalling (Fig. 3) and B 2 R-GFP cycling (Fig. 4) . Thus maximakinin may be considered as a biased agonist of the BK B 2 R, not because it induces a receptor conformation distinct from that induced by BK, but because differential receptor cycling will favour some signalling pathways (e.g., c-Fos) at the expense of others. Maximakinin is a natural amino acid sequence that points out to the N-terminus as the rate-limiting structural determinant of endosomal inactivation for BK, the only difference between the 2 peptides being in this region. This conjecture is confirmed by the striking effect of the N-terminally prolonged fluorescent BK analogue on B 2 R-GFP abundance and by the intermediary behaviour of other homolog peptides such as Lys-BK, when assessed for this outcome (Fig. 5) . Vacuolar ATPase is the proton pump that acidifies ensodomes, lysosomes and other organelles [20] ; its inhibitor bafilomycin A1 reduced the recycling of B 2 R-GFP in cells stimulated with BK for 3 h (Fig. 6) , supporting that the BK-inactivating enzyme(s)
operate at an acidic pH. Candidate endosomal peptidases that inactivate BK do not include endothelin-converting enzyme-1, while the latter is important for the cycling of substance P, calcitonin gene-related peptide and their respective receptors [7, 21] . Endosomal/lysosomal cathepsins include cysteinyl, seryl and aspartyl proteases [22] , and the effect of inhibitors of these enzyme classes on B 2 R-GFP recycling points out to the role of cysteinyl proteinase(s) in the inactivation of BK (Fig. 6 ). Cathepsin K has been previously shown to degrade BK, but has a very limited distribution (mostly osteoclasts) [23] . BK is reportedly not inactivated by cathepsins B, C, L and S [23] [24] [25] , while conflicting evidence has been produced for cathepsin H [23, 26] .
More work is needed to ascertain the identity of this endosomal kininase.
Biological and clinical implications
B 2 Rs are widely distributed in the gastrointestinal tract, including in enterocytes, neural plexus and smooth muscle cells [27, 28] , and may mediate the dissuasive effects of a persistent agonist such as maximakinin in a hypothetical predatory species in the wildlife. The toxicity of venom polycationic peptides may exceed the stimulation of the B 2 Rs, as Polistes kinin is a direct histamine releaser from mast cells, BK being ineffective in this respect [29] .
Large cargoes can be transported by the activated BK B 2 R, for instance antibody-based cargoes in excess of 2 MDa [30] . The particular issue with the BK B 2 R is the unpredictable affinity tolerance of extended agonist peptides. The extended sequence showcased by maximakinin may supply a naturally selected solution to this problem. For instance, a fluorescent B 2 R probe of higher affinity than CF--ACA-BK could be based on maximakinin and applied to cytofluorometric diagnostic. The long intracellular persistence of the peptide makes it ideal for in vivo B 2 R mapping, for instance if labelled with an isotope adapted to positron emission tomography; the agonist version was recently found superior to an antagonist ligand in a study of another receptor type [31] .
Conclusions
Maximakinin is the first known natural kinin sequence that elicits a prolonged cellular signalling, A.
B. 
